Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement. Its clinical programs include Mannan-binding lectin-associated serine protease-2 (MASP-2) (OMS721)-Lectin Pathway Disorders; PDE10 (OMS824)-CNS Disorders; peroxisome proliferator-activated receptor gamma (PPARy) (OMS405)-Addiction, and OMS201-Urology. Its preclinical programs include phosphodiesterase 7 (PDE7) (OMS527), Plasmin (OMS616), MASP-3 (OMS906)-Alternative Pathway Disorders, GPR17-CNS Disorders, GPR101-Metabolic Disorders, GPR151-CNS Disorders, GPR161-Cancer, GPR174-Immune Disorders, GPR183-Skeletal and Infectious Diseases, GPCR Platform and Antibody Platform.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: OMER
- CUSIP: 68214310
- Previous Close: $11.51
- 50 Day Moving Average: $10.10
- 200 Day Moving Average: $10.49
- 52-Week Range: $7.20 - $16.80
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -12.98
- P/E Growth: -0.08
- Market Cap: $495.67M
- Outstanding Shares: 42,915,000
- Beta: 3.16
- Net Margins: -189.16%
- Return on Assets: -104.29%
Companies Related to Omeros:
- Debt-to-Equity Ratio: -3.09%
- Current Ratio: 3.78%
- Quick Ratio: 3.69%
What is Omeros' stock symbol?
Omeros trades on the NASDAQ under the ticker symbol "OMER."
Where is Omeros' stock going? Where will Omeros' stock price be in 2017?
6 analysts have issued 1 year price targets for Omeros' shares. Their forecasts range from $8.63 to $75.00. On average, they anticipate Omeros' stock price to reach $33.23 in the next twelve months.
When will Omeros announce their earnings?
Omeros is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.
What are analysts saying about Omeros stock?
Here are some recent quotes from research analysts about Omeros stock:
According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (1/4/2017)
Maxim Group analysts commented, "Omeros announced a debt financing for $20M (effective on 5/18/16) from its existing credit facility with Oxford Finance and East West Bank." (5/19/2016)
Who owns Omeros stock?
Omeros' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Cpcm LLC (2.99%), State Street Corp (2.20%), Opaleye Management Inc. (0.62%), RTW Investments LP (0.60%), Allianz Asset Management AG (0.27%) and Baird Financial Group Inc. (0.22%). Company insiders that own Omeros stock include Gregory A Md Demopulos, Marcia S Kelbon, Peter A Md Demopulos and Thomas J Cable.
Who sold Omeros stock? Who is selling Omeros stock?
Omeros' stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP and Allianz Asset Management AG. Company insiders that have sold Omeros stock in the last year include Gregory A Md Demopulos, Marcia S Kelbon and Thomas J Cable.
Who bought Omeros stock? Who is buying Omeros stock?
Omeros' stock was bought by a variety of institutional investors in the last quarter, including Cpcm LLC, Opaleye Management Inc., Rubric Capital Management LP, State Street Corp, Dynamic Technology Lab Private Ltd, Baird Financial Group Inc., Raymond James Financial Services Advisors Inc. and First Allied Advisory Services Inc..
How do I buy Omeros stock?
Shares of Omeros can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Omeros stock cost?
One share of Omeros stock can currently be purchased for approximately $11.55.